Boston Scientific's Q2 results were essentially in line with consensus estimates as "some concerning areas" from Q1 persisted, such as Neuromod, but were offset by faster growth areas like Medsurg and Structural Heart, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The second half of 2019 acceleration in the core business, implied by the unchanged guidance, is achievable, says the analyst. He reiterates an Overweight rating on Boston Scientific shares with a $50 price target.
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here